The 2024 US Medical Eligibility Criteria for Contraceptive Use (US MEC) comprises recommendations for the use of specific contraceptive methods by persons who have certain characteristics or medical conditions. These recommendations for health care providers were updated by CDC after review of the scientific evidence and a meeting with national experts in Atlanta, Georgia, during ... Read more >

The 2024 US Selected Practice Recommendations for Contraceptive Use (US SPR) addresses a selected group of common, yet sometimes complex, issues regarding initiation and use of specific contraceptive methods. These recommendations for health care providers were updated by CDC after review of the scientific evidence and a meeting with national experts in Atlanta, Georgia, during ... Read more >

On March 4, 2024, the first daily over-the-counter oral contraceptive pill became available in the United States. This progestin-only pill (POP) is approved without a prescription for adolescents and adults to prevent pregnancy. The FDA did not approve this POP for menstrual suppression or other noncontraceptive indications. For both adults and adolescents, over-the-counter access to ... Read more >

Emergency contraception (EC) refers to several contraceptive options that can be used within a few days after unprotected or under protected intercourse or sexual assault to reduce the risk of pregnancy. Current EC options available in the United States include the copper intrauterine device (IUD), levonorgestrel (LNG) 52 mg IUD, oral LNG (such as Plan ... Read more >

In this clinical recommendation, we review the evidence supporting the use of the copper intrauterine device, levonorgestrel intrauterine devices and etonogestrel subdermal implant beyond the Food and Drug Administration approved duration of use for contraception (extended use). Clinicians should discuss effectiveness as well as other clinical considerations with patients to allow them to make contraceptive ... Read more >